Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Polish journal of pathology : official journal of the Polish Society of Pathologists

• Publication date

  2011-01-03

• Fields of study

  Medicine

• Identifiers
  PMID 21225497
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease

  2009cited by this paper
• Visfatin, low‐grade inflammation and body mass index (BMI)

  2008cited by this paper
• Pre‐B cell colony‐enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity

  2008cited by this paper
• Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.

  2008cited by this paper
• Non-alcoholic fatty liver disease and the metabolic syndrome: an update.

  2008cited by this paper
• The role of adipokines in liver fibrosis.

  2008cited by this paper
• Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome.

  2008cited by this paper
• The novel adipocytokine visfatin exerts direct cardioprotective effects

  2008cited by this paper
• Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells.

  2008cited by this paper
• Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties1

  2007influential reference
• Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.

  2007cited by this paper
• Pathology of fatty liver disease

  2007cited by this paper
• Adipokines and cytokines in non‐alcoholic fatty liver disease

  2007influential reference
• Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome

  2007cited by this paper
• Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.

  2006cited by this paper
• Histological Findings in the Liver Before and After Gastric Bypass

  2006cited by this paper
• Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin

  2006cited by this paper
• Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans.

  2006cited by this paper
• Histological assessment of non‐alcoholic fatty liver disease

  2006cited by this paper
• Predictors of Nonalcoholic Steatohepatitis (NASH) in Obese Patients Undergoing Gastric Bypass

  2005cited by this paper
• Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Morbidly Obese Patients

  2005cited by this paper
• The Comparison of Scoring Scales for Liver Biopsy Assessment in Morbidly Obese Patients Undergoing Bariatric Surgery

  2005cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Cytokines and the pathogenesis of non-alcoholic steatohepatitis

  2005cited by this paper
• Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.

  2005cited by this paper
• Review article: the pathogenesis of fibrosis in non‐alcoholic steatohepatitis

  2005cited by this paper
• Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes.

  2005cited by this paper
• Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.

  2005influential reference
• Recent concepts in non‐alcoholic fatty liver disease

  2005cited by this paper
• Liver Damage in Severely Obese Patients: a Clinical-Biochemical-Morphologic Study on 1,000 Liver Biopsies

  2004cited by this paper
• Steatohepatitis: a tale of two "hits"?

  1998cited by this paper
• The nomenclature of chronic hepatitis: time for a change.

  1995cited by this paper
• Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor

  1994cited by this paper
• Nonalcoholic fatty liver disease.

  1986cited by this paper

• Relationship of visfatin with obesity and osteoporosis in patients with inflammatory bowel disease: a narrative review

  2025cites this paper
• The Role of Visfatin in Gastric and Esophageal Cancer: From Biomarker to Therapeutic Target

  2025cites this paper
• Both prolonged high-fat diet consumption and calorie restriction boost hepatic NAD+ metabolism in mice.

  2023cites this paper
• The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease

  2023cites this paper
• Role of visfatin in obesity-induced insulin resistance

  2022cites this paper
• Immunohistochemical identification and assessment of the location of leptin, visfatin and chemerin in the liver of men with different body mass index

  2022influential citation
• Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients – a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown

  2022cites this paper
• Role of adipokines (omentin and visfatin) in coronary artery disease.

  2022cites this paper
• Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?

  2022cites this paper
• Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis

  2021cites this paper
• Visfatin exacerbates hepatic inflammation and fibrosis in a methionine‐choline‐deficient diet mouse model

  2021cites this paper
• Visfatin as a Promising Marker of Cardiometabolic Risk.

  2021cites this paper
• NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential

  2020cites this paper
• Hepatokines and adipokines in NASH-related hepatocellular carcinoma.

  2020cites this paper
• Visfatin serum concentration and hepatic mRNA expression in chronic hepatitis C

  2019cites this paper
• Association Between Visfatin and Hepatic Steatosis in the General Population During Long-Term Follow-Up

  2019cites this paper
• Ghrelin, visfatin and irisin in children with short bowel syndrome.

  2019cites this paper
• Visfatin and chemerin levels correspond with inflammation and might reflect the bridge between metabolism, inflammation and fibrosis in patients with systemic sclerosis

  2019cites this paper
• Nicotinamide and NAFLD: Is There Nothing New Under the Sun?

  2019cites this paper
• Adipose Organ Development and Remodeling.

  2018cites this paper
• The Effects on Obesity Related Peptides of Laparoscopic Gastric Band Applications in Morbidly Obese Patients

  2018cites this paper
• Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease

  2018cites this paper
• Underrated enemy – from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract

  2018cites this paper
• Effects of Non-Alcoholic Fatty Liver Disease on Visfatin and IL-6 Levels in Mice: An Immunohistochemical Study

  2018cites this paper
• The relationship between serum visfatin and the progress of chronic viral hepatitis B cirrhosis.

  2017cites this paper
• Vaspin mRNA levels in the liver of morbidly obese women with nonalcoholic fatty liver disease.

  2017cites this paper
• Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.

  2017cites this paper
• Oleate ameliorates palmitate-induced reduction of NAMPT activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells

  2017cites this paper
• The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease

  2017cites this paper
• Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection

  2017cites this paper
• Serum Levels of Visfatin, Omentin and Irisin in Patients with End-Stage Lung Disease Before and After Lung Transplantation

  2017cites this paper
• Associations of adipose tissue characteristics in non-alcoholic fatty liver disease and disturbed sex steroid profile in obese male patients

  2016cites this paper
• Effect of curcumin on visfatin and zinc-α2-glycoprotein in a rat model of non-alcoholic fatty liver disease.

  2016cites this paper
• The relationship between visfatin, liver inflammation, and acute phase reactants in chronic viral hepatitis B

  2016cites this paper
• The Correlation Between Serum Adipokines and Liver Cell Damage in Non-Alcoholic Fatty Liver Disease

  2016cites this paper
• Adipokines in nonalcoholic fatty liver disease.

  2016cites this paper
• Association of recently described adipokines with liver histology in biopsy‐proven non‐alcoholic fatty liver disease: a systematic review

  2016cites this paper
• Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.

  2016cites this paper
• New Developments in 1H NMR-linked Metabolomics: Identification of New Biomarkers for the Metabolomic Classification of Niemann-Pick Disease, Type C1, and its Response to Treatment

  2016cites this paper
• Hepatic NAD salvage pathway is enhanced in mice on a high-fat diet.

  2015cites this paper
• Physiological and pathophysiological roles of NAMPT and NAD metabolism

  2015cites this paper
• Austin Biomarkers & Diagnosis Adipokines in Hepatic Angiogenesis

  2015cites this paper
• Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection

  2015cites this paper
• A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study.

  2014cites this paper
• Resistin and visfatin in steatotic and non-steatotic livers in the setting of partial hepatectomy under ischemia-reperfusion.

  2014cites this paper
• Serum visfatin in nonalcoholic fatty liver disease.

  2014cites this paper
• Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update.

  2014cites this paper
• Adipokines in Nonalcoholic Fatty Liver Disease

  2014cites this paper
• CIRCULATING VISFATIN AND PROINFLAMMATORY CYTOKINE LEVELS IN NONALCOHOLIC FATTY LIVER DISEASE

  2014cites this paper
• A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.

  2013cites this paper
• Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.

  2013cites this paper
• Adiponectin and resistin protect steatotic livers undergoing transplantation.

  2013cites this paper
• Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.

  2013cites this paper
• Visfatin/Nampt: An Adipokine with Cardiovascular Impact

  2013cites this paper
• Liver Fibrogenesis in Non-Alcoholic Steatohepatitis

  2012cites this paper
• THE ROLE OF NEW ADIPOKINES IN THE PATHOGENIC MECHANISMS OF CHRONIC HEPATITIS C 1

  2012cites this paper
• Visfatin Levels in Nonalcoholic Fatty Liver Disease

  2012cites this paper
• Visfatina: un potencial biomarcador de esteatohepatitis no alcohólica en mujeres con obesidad mórbida no diabéticas

  2012cites this paper